Epigenetic scores for the circulating proteome as tools for disease prediction.
Adolescent
Adult
Aged
Aged, 80 and over
Aging
Biomarkers
Cardiovascular Diseases
/ diagnosis
DNA Methylation
/ genetics
Diabetes Mellitus
/ diagnosis
Epigenesis, Genetic
Epigenomics
/ methods
Female
Humans
Life Style
Male
Middle Aged
Neoplasms
/ diagnosis
Proteome
/ genetics
Risk Factors
Scotland
Young Adult
aging
biomarker
epidemiology
epigenetic
genetics
genomics
global health
human
morbiditiy
prediction
proteomics
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
13 01 2022
13 01 2022
Historique:
received:
30
06
2021
accepted:
11
01
2022
pubmed:
14
1
2022
medline:
18
3
2022
entrez:
13
1
2022
Statut:
epublish
Résumé
Protein biomarkers have been identified across many age-related morbidities. However, characterising epigenetic influences could further inform disease predictions. Here, we leverage epigenome-wide data to study links between the DNA methylation (DNAm) signatures of the circulating proteome and incident diseases. Using data from four cohorts, we trained and tested epigenetic scores (EpiScores) for 953 plasma proteins, identifying 109 scores that explained between 1% and 58% of the variance in protein levels after adjusting for known protein quantitative trait loci (pQTL) genetic effects. By projecting these EpiScores into an independent sample (Generation Scotland; n = 9537) and relating them to incident morbidities over a follow-up of 14 years, we uncovered 137 EpiScore-disease associations. These associations were largely independent of immune cell proportions, common lifestyle and health factors, and biological aging. Notably, we found that our diabetes-associated EpiScores highlighted previous top biomarker associations from proteome-wide assessments of diabetes. These EpiScores for protein levels can therefore be a valuable resource for disease prediction and risk stratification. Although our genetic code does not change throughout our lives, our genes can be turned on and off as a result of epigenetics. Epigenetics can track how the environment and even certain behaviors add or remove small chemical markers to the DNA that makes up the genome. The type and location of these markers may affect whether genes are active or silent, this is, whether the protein coded for by that gene is being produced or not. One common epigenetic marker is known as DNA methylation. DNA methylation has been linked to the levels of a range of proteins in our cells and the risk people have of developing chronic diseases. Blood samples can be used to determine the epigenetic markers a person has on their genome and to study the abundance of many proteins. Gadd, Hillary, McCartney, Zaghlool et al. studied the relationships between DNA methylation and the abundance of 953 different proteins in blood samples from individuals in the German KORA cohort and the Scottish Lothian Birth Cohort 1936. They then used machine learning to analyze the relationship between epigenetic markers found in people’s blood and the abundance of proteins, obtaining epigenetic scores or ‘EpiScores’ for each protein. They found 109 proteins for which DNA methylation patterns explained between at least 1% and up to 58% of the variation in protein levels. Integrating the ‘EpiScores’ with 14 years of medical records for more than 9000 individuals from the Generation Scotland study revealed 130 connections between EpiScores for proteins and a future diagnosis of common adverse health outcomes. These included diabetes, stroke, depression, various cancers, and inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease. Age-related chronic diseases are a growing issue worldwide and place pressure on healthcare systems. They also severely reduce quality of life for individuals over many years. This work shows how epigenetic scores based on protein levels in the blood could predict a person’s risk of several of these diseases. In the case of type 2 diabetes, the EpiScore results replicated previous research linking protein levels in the blood to future diagnosis of diabetes. Protein EpiScores could therefore allow researchers to identify people with the highest risk of disease, making it possible to intervene early and prevent these people from developing chronic conditions as they age.
Autres résumés
Type: plain-language-summary
(eng)
Although our genetic code does not change throughout our lives, our genes can be turned on and off as a result of epigenetics. Epigenetics can track how the environment and even certain behaviors add or remove small chemical markers to the DNA that makes up the genome. The type and location of these markers may affect whether genes are active or silent, this is, whether the protein coded for by that gene is being produced or not. One common epigenetic marker is known as DNA methylation. DNA methylation has been linked to the levels of a range of proteins in our cells and the risk people have of developing chronic diseases. Blood samples can be used to determine the epigenetic markers a person has on their genome and to study the abundance of many proteins. Gadd, Hillary, McCartney, Zaghlool et al. studied the relationships between DNA methylation and the abundance of 953 different proteins in blood samples from individuals in the German KORA cohort and the Scottish Lothian Birth Cohort 1936. They then used machine learning to analyze the relationship between epigenetic markers found in people’s blood and the abundance of proteins, obtaining epigenetic scores or ‘EpiScores’ for each protein. They found 109 proteins for which DNA methylation patterns explained between at least 1% and up to 58% of the variation in protein levels. Integrating the ‘EpiScores’ with 14 years of medical records for more than 9000 individuals from the Generation Scotland study revealed 130 connections between EpiScores for proteins and a future diagnosis of common adverse health outcomes. These included diabetes, stroke, depression, various cancers, and inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease. Age-related chronic diseases are a growing issue worldwide and place pressure on healthcare systems. They also severely reduce quality of life for individuals over many years. This work shows how epigenetic scores based on protein levels in the blood could predict a person’s risk of several of these diseases. In the case of type 2 diabetes, the EpiScore results replicated previous research linking protein levels in the blood to future diagnosis of diabetes. Protein EpiScores could therefore allow researchers to identify people with the highest risk of disease, making it possible to intervene early and prevent these people from developing chronic conditions as they age.
Identifiants
pubmed: 35023833
doi: 10.7554/eLife.71802
pii: 71802
pmc: PMC8880990
doi:
pii:
Substances chimiques
Biomarkers
0
Proteome
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/F019394/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 216767/Z/19/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 221890/Z/20/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700704
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : P2C HD042849
Pays : United States
Organisme : Medical Research Council
ID : MR/R024065/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00007/10
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M013111/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : RF1 AG073593
Pays : United States
Organisme : Wellcome Trust
ID : 104036/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 220857/Z/20/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203771/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108890/Z/15/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG054628
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066614
Pays : United States
Organisme : Medical Research Council
ID : G1001245
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701120
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K026992/1
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CZD/16/6
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2022, Gadd et al.
Déclaration de conflit d'intérêts
DG, DM, SZ, AS, YC, CF, CN, AC, RF, SH, RW, LS, ET, CG, AP, MW, JG, AM, ID, DP, CH, PV, SC, KE, AM, KS No competing interests declared, RH has received consultant fees from Illumina, RM has received speaker fees from Illumina and is an advisor to the Epigenetic Clock Development Foundation
Références
Nat Commun. 2020 Dec 16;11(1):6397
pubmed: 33328453
Am J Epidemiol. 2003 Aug 15;158(4):357-64
pubmed: 12915501
J Appl Physiol (1985). 2000 Oct;89(4):1499-504
pubmed: 11007588
Nat Rev Drug Discov. 2015 Dec;14(12):857-77
pubmed: 26493766
Alzheimers Dement (Amst). 2018 Jun 21;10:429-437
pubmed: 30167451
BMC Genomics. 2015 Jun 06;16:437
pubmed: 26048416
Int J Epidemiol. 2018 Aug 1;47(4):1042-1042r
pubmed: 29546429
BMC Bioinformatics. 2012 May 08;13:86
pubmed: 22568884
Clin Epigenetics. 2020 Jul 31;12(1):115
pubmed: 32736664
Epigenomics. 2019 Oct;11(13):1469-1486
pubmed: 31466478
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Genome Med. 2018 Oct 22;10(1):75
pubmed: 30348214
Genome Biol. 2018 Sep 27;19(1):136
pubmed: 30257690
Cell. 2021 Mar 18;184(6):1455-1468
pubmed: 33657411
Neurotox Res. 2019 Jul;36(1):163-174
pubmed: 30953275
Nature. 2018 Jun;558(7708):73-79
pubmed: 29875488
Ann Rheum Dis. 2019 Nov;78(11):1463-1471
pubmed: 31511227
Sci Transl Med. 2018 May 16;10(441):
pubmed: 29769288
EBioMedicine. 2018 Nov;37:214-220
pubmed: 30389506
Genome Biol. 2019 May 28;20(1):107
pubmed: 31138268
Int J Epidemiol. 2013 Jun;42(3):689-700
pubmed: 22786799
Nature. 2016 Aug 4;536(7614):41-47
pubmed: 27398621
J Proteomics. 2012 Jan 4;75(3):783-95
pubmed: 21989264
JAMA. 2016 Jun 21;315(23):2532-41
pubmed: 27327800
Nat Commun. 2018 Sep 18;9(1):3853
pubmed: 30228274
Nat Commun. 2019 Jul 18;10(1):3160
pubmed: 31320639
Int J Epidemiol. 2012 Dec;41(6):1576-84
pubmed: 22253310
Mol Immunol. 2017 Sep;89:36-43
pubmed: 28576324
Nat Commun. 2017 Feb 27;8:14357
pubmed: 28240269
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Nat Commun. 2020 Jan 3;11(1):15
pubmed: 31900413
Ann Pediatr Endocrinol Metab. 2017 Sep;22(3):145-152
pubmed: 29025199
Diabetes. 2020 Aug;69(8):1843-1853
pubmed: 32385057
PLoS One. 2010 Dec 07;5(12):e15004
pubmed: 21165148
Nat Commun. 2020 Jun 8;11(1):2865
pubmed: 32513961
Front Immunol. 2020 Dec 10;11:599417
pubmed: 33362783
Genome Biol. 2021 Jun 29;22(1):194
pubmed: 34187551
Nat Commun. 2017 Nov 28;8(1):1826
pubmed: 29184056
J Gerontol A Biol Sci Med Sci. 2021 Nov 15;76(12):2284-2292
pubmed: 33595649
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Genome Res. 2014 Nov;24(11):1725-33
pubmed: 25249537
Mol Neurodegener. 2017 Sep 18;12(1):66
pubmed: 28923083
Int J Epidemiol. 2018 Feb 1;47(1):13-14g
pubmed: 29040551
J Neuroimmunol. 2014 Nov 15;276(1-2):213-8
pubmed: 25262158
Exp Mol Med. 2016 Mar 11;48:e220
pubmed: 26964836
Neurology. 2021 Dec 7;97(23):e2340-e2352
pubmed: 34789543
Aging (Albany NY). 2019 Jan 21;11(2):303-327
pubmed: 30669119
Nat Genet. 2021 Sep;53(9):1311-1321
pubmed: 34493871
Nat Neurosci. 2014 Sep;17(9):1138-40
pubmed: 25157507
Wellcome Open Res. 2020 Dec 7;5:283
pubmed: 33969230
Nat Commun. 2017 Mar 17;8:14617
pubmed: 28303888
Genome Med. 2020 Jul 8;12(1):60
pubmed: 32641083
Cell Syst. 2020 Jul 22;11(1):11-24.e4
pubmed: 32619549
Elife. 2018 Dec 21;7:
pubmed: 30575519
Cell Syst. 2021 Aug 18;12(8):780-794.e7
pubmed: 34139154
Wellcome Open Res. 2021 Oct 18;6:277
pubmed: 35999909
Hum Mol Genet. 2014 Jan 15;23(2):534-45
pubmed: 24014485
Clin Epigenetics. 2020 Jul 27;12(1):113
pubmed: 32718350
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
JCI Insight. 2021 Mar 8;6(5):
pubmed: 33591955
Inflamm Bowel Dis. 2014 Dec;20(12):2483-92
pubmed: 25185685
Mol Syst Biol. 2015 Feb 04;11(1):786
pubmed: 25652787
Aging Dis. 2019 Apr 1;10(2):429-462
pubmed: 31011487
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
Chest. 2021 Jun;159(6):2244-2253
pubmed: 33434499
Genet Epidemiol. 2018 Feb;42(1):20-33
pubmed: 29034560
Diabetes. 2020 Dec;69(12):2766-2778
pubmed: 32928870
Clin Epigenetics. 2020 Mar 26;12(1):49
pubmed: 32216821
Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6
pubmed: 18940858